Aia Group LTD Incyte Corp Transaction History

Aia Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	SELL	$70.23 - $86.01 $94,670 - $115,941	-1,348 Reduced 15.85%	7,157 $517,000
Q4 2022 Jan 31, 2023	BUY	$67.18 - $84.11 $342,752 - $429,129	5,102 Added 149.93%	8,505 $683,000
Q3 2022 Nov 04, 2022	SELL	$66.18 - $82.86 $138,713 - $173,674	-2,096 Reduced 38.12%	3,403 $227,000
Q2 2022 Aug 11, 2022	BUY	$66.18 - $83.18 $363,923 - $457,406	5,499 New	5,499 $418,000
Q1 2022 May 06, 2022	SELL	$66.02 - $79.71 $123,787 - $149,456	-1,875 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $118,762 - $138,956	1,875 New	1,875 $138,000
Q2 2021 Aug 03, 2021	SELL	$79.87 - $87.53 $857,164 - $939,371	-10,732 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $815,846 - $1.08 Million	10,732 New	10,732 $872,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

Stay updated on Aia Group LTD with notifications on news.